EBC-46

Consumer Reports

Immune System Support and Blushwood Berry Extract: What Users Are Reporting in Early 2026

A growing number of blushwood berry extract users report perceived improvements in immune function. Here is what they describe and what the science can currently explain.

Natural Source

Pollination Biology of Fontainea Picrosperma: Why Blushwood Berry Fruiting Is Unpredictable

The blushwood tree depends on a narrow set of pollinators and environmental conditions. Understanding its reproductive biology explains why fruit yield varies so dramatically.

Human Trials

Injection Site Pharmacology in EBC-46 Trials: Drug Retention, Diffusion, and Local Bioavailability

How EBC-46 behaves after intratumoral injection — drug retention within the tumour mass, local diffusion patterns, and why systemic exposure remains minimal.

Mechanism of Action

Reactive Oxygen Species and EBC-46: How Oxidative Stress Contributes to Tumour Cell Death

PKC activation by EBC-46 triggers a burst of reactive oxygen species inside tumour cells. This oxidative stress cascade is a key mechanism in its anti-cancer effect.

Regulatory

Clinical Hold and Safety Review: How the FDA Monitors EBC-46 Trial Progress

The FDA can pause any clinical trial through a clinical hold order. Here is how that oversight mechanism applies to intratumoral EBC-46 research.

EBC-46

Digestive Health and Blushwood Berry Extract: What Users Report About Gut Wellness and EBC-46

A growing subset of blushwood berry extract users report improvements in digestive comfort, bloating, and gut regularity alongside their primary reasons for supplementation.

EBC-46

Propagation Techniques for Fontainea picrosperma: Seed Germination, Grafting, and Clonal Methods

Scaling tigilanol tiglate production depends on reliably propagating Fontainea picrosperma through seed germination, vegetative grafting, and emerging clonal techniques.

EBC-46

Adverse Event Profiles in Tigilanol Tiglate Trials: Local Tissue Response, Pain Management, and Recovery

Clinical trial data reveals a consistent pattern of local adverse events following tigilanol tiglate injection, including pain, swelling, and wound formation that resolve over weeks.

EBC-46

Calcium Signalling and PKC Activation: How EBC-46 Triggers Rapid Intracellular Calcium Flux

PKC activation by EBC-46 initiates a rapid calcium signalling cascade that contributes to tumour cell death, immune recruitment, and vascular disruption at the injection site.

EBC-46

GMP Manufacturing Requirements for Tigilanol Tiglate: What Pharmaceutical-Grade EBC-46 Production Demands

Good Manufacturing Practice standards govern how tigilanol tiglate must be produced, tested, and released before it can enter human clinical trials or reach the market.

Consumer Reports

Joint Pain, Mobility, and Blushwood Berry Extract: What Users Are Saying in 2026

A growing number of blushwood berry extract users are reporting improvements in joint pain and mobility, adding to an evolving body of consumer-reported outcomes.

Human Trials

Wound Healing After Intratumoral EBC-46 Injection: What Phase I Data Reveals

Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.